13 / 24
Page 70
conferenceseries
.com
Volume 7
OMICS Journal of Radiology
Radiology and Oncology 2018
July 16-17, 2018
July 16-17, 2018 Dubai, UAE
Radiology and Oncology
2
nd
World Congress on
Imaging with new PET tracers in oncology
Alka Chengapa
Apollo Hospitals, India
N
ew PET tracers in oncology-presently 18F-fluorodeoxyglucose (18-F FDG) are the workhorse of PET imaging in Oncology.
However, the main disadvantage is its non-specificity. HCC, neuroendocrine tumors, prostate tumors, CNS tumors and renal
cell carcinomas may show low or absent FDG uptake. New tracers have been developed to give better sensitivity and specificity.
Some are used in clinical practice, while some are still undergoing clinical and pre-clinical trials. Those that are already used
for clinical applications include 11C- and 18F-Choline, 11C-Methionine and 18F-FET, 18F-DOPA, 68Ga-DOTA-somatostatin
analogues, 11C-acetate and 18F-FLT and 68Ga-PSMA.stu . Other tracers are used in PET not as markers of metabolic activity but
as markers of hypoxia inside big neoplastic masses. These compounds (the most important are 18F-MISO, 64Cu-ATSM and 18F-
EF5) which highlight the presence of hypoxic areas are useful for patients who must be treated with radiotherapy. In fact, it is well
known that hypoxia is one the strongest factors associated for treatment resistance and hypoxic areas should be recognized and
over-treated compared to non-hypoxic malignant tissues.
OMICS J Radiol 2018, Volume 7
DOI: 10.4172/2167-7964-C1-022